Trial Profile
An Investigation of the Antidepressant Efficacy of a Selective, High, Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs AZD 2327 (Primary)
- Indications Anxiety; Major depressive disorder
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 05 Mar 2012 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
- 05 Mar 2012 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
- 05 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.